Pro-Life Members Urge the Supreme Court to Consider FDA Authorization of Chemical Abortion
Americans United for Life (AUL) filed an amicus curiae brief Wednesday on behalf of 92 members of the House of Representatives and 17 members of the Senate. Rep. August Pfluger of Texas led the House delegation and Sen. Cindy Hyde-Smith of Mississippi led the Senate delegation.
The brief, which addresses the case of Alliance for Hippocratic Medicine v. Food and Drug Administration, argues that the FDA’s reckless actions have endangered women and girls seeking chemical abortion and encourages the Court to review all the changes the FDA has made to its chemical abortion regulations since its initial approval of mifepristone in 2000.
AUL has filed briefs on behalf of pro-life members of Congress at every stage of this case.
Litigation Counsel Carolyn McDonnell said, “This case is about how the FDA’s unlawful actions have endangered patient health and safety. Contrary to federal law, the FDA did not perform pediatric studies to ensure the drugs, dosages, and method of administration are safe for girls seeking chemical abortions. By approving and deregulating chemical abortion drugs, the FDA bolstered abortion businesses at the expense of the health and safety of women and girls.”
Federal Policy Director Jesse Southerland said, “By approving and then deregulating mifepristone, the FDA has disregarded federal law in the drug approval process. Why do we have laws that protect patient safety if the FDA isn’t going to follow them?”
Read the full brief here.
